• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

    39.55 -0.20 (-0.50%)
    Streaming Delayed Price Updated: 1:14 PM EDT, Apr 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Crinetics Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
    Application supported by comprehensive clinical program, including two positive Phase 3 trials evaluating once-daily oral paltusotine in acromegaly 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
    First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAH 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
    Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
    Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
    Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor... 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.